씨티씨바이오

060590KOSDAQ의약품 제조업

42.4 / 100

Reference Date: 2026-07-24

Financial Score11.5 / 40

News Sentiment16.9 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is above the industry average but the high debt ratio poses financial risk. Slightly down 2.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

CTC Bio operates in the animal and human pharmaceutical sectors, leveraging core technologies such as microbial fermentation, drug coating, and DDS to develop diverse products. Its key revenue drivers include award-winning products like CTCZYME and ODF films, while the company actively manages foreign exchange risks to strengthen its global competitiveness.

Number of Employees

237people

Average Salary

46.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

21.24Industry Average 11.231.5Point

1.9x industry avg (risky)

PBR

0.97Industry Average 0.812.5Point

Higher than industry avg (caution)

ROE

4.55Industry Average 4.014.0Point

In line with industry avg

Debt Ratio

27.63Industry Average 12.430.0Point

2.2x industry avg (risky)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼4.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲135.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -7.0% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 67.5

Positive
코스맥스펫, 생산 공간 4배 키웠다…'400억 투자' 증평 신공장 가동
코스맥스펫의 증평 신공장 가동으로 반려동물 헬스케어 제품 생산 능력이 확대되어 시장 경쟁력 강화가 예상됩니다.
Neutral
코스맥스펫, 증평 신공장 가동…반려동물 영양제·뷰티 '생산기지'
코스맥스펫의 증평 신공장 가동 소식은 관련 산업 확장에 긍정적이나, 씨티씨바이오(060590)와 직접적인 연관성이 없다.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 2,910Won52-week high 7,45052-week low 2,770

1-month return2.0Point

1m -2.35% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0